COMPARE is the world’s first head-to-head prospective, RCT (1:1) comparing low dose Ranger DCB (2 μg/mm2) to higher dose IN.PACT DCB (3.5 μg/mm2).

 

Ranger demonstrated similar primary patency1 with half the total drug dose.2

24-Month Results Presented at LINC 2021 by Sabine Steiner, MD

12-Month Results Published in European Heart Journal  

 Kaplan-Meier Primary Patency Results

Target Lesion Length = ~126 mm Total Occlusions = ~42% Moderate to Severe Calcium = ~54%

1. COMPARE Clinical Trial 12-Month Results presented by Sabine Steiner, MD. LINC 2020. 12-Month Primary Endpoints: Binary Primary Patency = 83.0% for Ranger DCB and 81.5% for IN.PACT DCB (Pnon-inferiority <0.01). Freedom from Major Adverse Events = 91.0% for Ranger DCB and 92.6% for IN.PACT DCB (Pnon-inferiority <0.01).
2. Based on total drug dose for 4mmx60mm or averages for full size matrix per the IN.PACT™ Admiral™ Drug-Coated Balloon Instructions for Use, http://www.medtronic.com, and the Ranger™ Paclitaxel-Coated PTA Balloon Catheter Instructions for Use.
* Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.

 

 

12-MONTH PRIMARY ENDPOINTS RANGER IN.PACT p-value
Binary Primary Patency 83.0%
(156/188)
81.5%
(141/173)
Pnon-inferiority <0.01
Freedom from major adverse events 91.0%
(182/200)
92.6%
(175/189)
Pnon-inferiority <0.01
Both primary endpoints met.
 
TRIAL DETAILS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Excipient TransPax™ citrate ester Urea N/A
Paclitaxel dose density 2.0 µg/mm2 3.5 µg/mm2 N/A
Average total paclitaxel dose per patient in trial 6,971 µg 13,035 µg <0.0001

 

 

BASELINE CHARACTERISTICS RANGER IN.PACT p-value
Age (year) 68.2 68.4 0.79
Female 38.2% 36.2% 0.68
Current/Former Smoker 77.3% 75.3% 0.63*
Total Occlusions 41% 43% 0.62
Total Occlusion Length 131 mm 113 mm 0.23
Target Lesion Length 124 mm 128 mm 0.65
Moderate to Severe Calcification** 51% 57% ***
Diabetics 31% 37% 0.18
* p-value based on entire distribution. Never, Former or Current Smokers
** PACSS Grade 3/4 may be considered similar to moderate/severe calcification
*** p-value for entire distribution of PACSS Calcium Grades 0, 1, 2, 3, 4 calcium for RANGER vs IN.PACT. p-value was 0.20.

  

 

12 MONTH KEY RESULTS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Mortality: All Cause 2.5% 1.6% 0.73
Mortality: Device or procedure related 0% 0% N/A
CD-TLR 9.0% 7.4% 0.59

 

 

24 MONTH KEY RESULTS RANGER
(n=207)
IN.PACT
(n=207)
p-value
Mortality: All Cause 3.6% (7/196) 2.2% (4/181) 0.6
Mortality: Device or procedure related 0% 0% 1.0
CD-TLR 17.3% 13.0% 0.3

 

 

Definitions

Primary safety endpoint — composite of freedom from device and procedure-related death through 30-days and freedom from major target limb amputation and CD-TLR through 12 months post index-procedure.

Primary efficacy endpoint — primary patency at 12 months defined as absence of clinically-driven target lesion revascularization (CD-TLR) or binary restenosis determined as a peak systolic velocity ratio > 2.4 evaluated by duplex ultrasound core laboratory analysis.

CD-TLR — a reintervention performed for ≥ 50% diameter stenosis (confirmed by angiography) within ± 5 mm proximal and/or distal to the target lesion after documentation of recurrent clinical symptoms of PAD (increase of 1 Rutherford class or more) and/or drop of ABI (≥20% or ≥0.15 when compared to maximum early postprocedural level).

 

Ranger is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.

 

Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top